Mathematical Modeling of Spatio‐Temporal Dynamics of a Single Bone Multicellular Unit

During bone remodeling, bone‐resorbing osteoclasts and bone‐forming osteoblasts are organized in bone multicellular units (BMUs), which travel at a rate of 20–40 μm/d for 6–12 mo, maintaining a cylindrical structure. However, the interplay of local BMU geometry with biochemical regulation is poorly understood. We developed a mathematical model of BMU describing changes in time and space of the concentrations of proresorptive cytokine RANKL and its inhibitor osteoprotegerin (OPG), in osteoclast and osteoblast numbers, and in bone mass. We assumed that osteocytes surrounding a microfracture produce RANKL, which attracted osteoclasts. OPG and RANKL were produced by osteoblasts and diffused through bone, RANKL was eliminated by binding to OPG and RANK. Osteoblasts were coupled to osteoclasts through paracrine factors. The evolution of the BMU arising from this model was studied using numerical simulations. Our model recapitulated the spatio‐temporal dynamics observed in vivo in a cross‐section of bone. In response to a RANKL field, osteoclasts moved as a well‐confined cutting cone. The coupling of osteoclasts to osteoblasts allowed for sufficient recruitment of osteoblasts to the resorbed surfaces. The RANKL field was the highest at the microfracture in front of the BMU, whereas the OPG field peaked at the back of the BMU, resulting in the formation of a RANKL/OPG gradient, which strongly affected the rate of BMU progression and its size. Thus, the spatial organization of a BMU provides important constraints on the roles of RANKL and OPG as well as possibly other regulators in determining the outcome of remodeling in the BMU.

[1]  Kosaku Kurata,et al.  Bone Marrow Cell Differentiation Induced by Mechanically Damaged Osteocytes in 3D Gel‐Embedded Culture , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  S. Yamasaki,et al.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.

[3]  Alexander G Robling,et al.  Biomechanical and molecular regulation of bone remodeling. , 2006, Annual review of biomedical engineering.

[4]  P. Mantyh,et al.  Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.

[5]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[6]  Svetlana V Komarova,et al.  Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone. , 2005, Endocrinology.

[7]  Mark L. Johnson,et al.  Osteocytes, mechanosensing and Wnt signaling. , 2008, Bone.

[8]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[9]  C. Milgrom,et al.  Reliable simulations of the human proximal femur by high-order finite element analysis validated by experimental observations. , 2007, Journal of biomechanics.

[10]  B. Riggs,et al.  The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. , 2000, Endocrinology.

[11]  Theo H Smit,et al.  Strain-derived canalicular fluid flow regulates osteoclast activity in a remodelling osteon--a proposal. , 2003, Journal of biomechanics.

[12]  Olivier Verborgt,et al.  Spatial Distribution of Bax and Bcl‐2 in Osteocytes After Bone Fatigue: Complementary Roles in Bone Remodeling Regulation? , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  Benedikt Hallgrímsson,et al.  Three-dimensional microcomputed tomography imaging of basic multicellular unit-related resorption spaces in human cortical bone. , 2006, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[14]  Samuel K. Cho,et al.  Mechanical Loading Differentially Regulates Membrane‐Bound and Soluble RANKL Availability in MC3T3‐E1 Cells , 2006, Annals of the New York Academy of Sciences.

[15]  L. Xing,et al.  Functions of RANKL/RANK/OPG in bone modeling and remodeling. , 2008, Archives of biochemistry and biophysics.

[16]  D. Sheppard,et al.  α9β1: A Novel Osteoclast Integrin That Regulates Osteoclast Formation and Function , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  D B Burr,et al.  Muscle Strength, Bone Mass, and Age‐Related Bone Loss , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  Svetlana V Komarova,et al.  Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. , 2003, Bone.

[19]  Vincent Lemaire,et al.  Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. , 2004, Journal of theoretical biology.

[20]  G. Roodman Regulation of Osteoclast Differentiation , 2006, Annals of the New York Academy of Sciences.

[21]  V. Chernick,et al.  Remodeling , 2006 .

[22]  H. Frost Skeletal structural adaptations to mechanical usage (SATMU): 2. Redefining Wolff's Law: The remodeling problem , 1990, The Anatomical record.

[23]  David J J de Gorter,et al.  Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. , 2008, The Journal of bone and joint surgery. American volume.

[24]  J. Eisman,et al.  Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. , 2001, The Journal of endocrinology.

[25]  P. Härkönen,et al.  Estrogen and Testosterone Use Different Cellular Pathways to Inhibit Osteoclastogenesis and Bone Resorption , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  S. Komarova,et al.  Complex Dynamics of Osteoclast Formation and Death in Long-Term Cultures , 2008, PloS one.

[27]  David B. Burr,et al.  Remodeling and the repair of fatigue damage , 2005, Calcified Tissue International.

[28]  Flemming Melsen,et al.  Cancellous Bone Remodeling Occurs in Specialized Compartments Lined by Cells Expressing Osteoblastic Markers , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  Peter Pivonka,et al.  Model structure and control of bone remodeling: a theoretical study. , 2008, Bone.

[30]  S. Reddy,et al.  Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures. , 1999, The Journal of clinical investigation.

[31]  B. Troen Molecular mechanisms underlying osteoclast formation and activation , 2003, Experimental Gerontology.

[32]  T. Martin,et al.  Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis , 2002 .

[33]  Gideon A. Rodan,et al.  Control of osteoblast function and regulation of bone mass , 2003, Nature.

[34]  S. Reddy Regulatory mechanisms operative in osteoclasts. , 2004, Critical reviews in eukaryotic gene expression.

[35]  T. Martin,et al.  Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. , 2002, Bone.

[36]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[37]  H. Frost,et al.  Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff's Law: The bone modeling problem , 1990, The Anatomical record.

[38]  C. Haipek,et al.  Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. , 1994, The Journal of biological chemistry.

[39]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[40]  J. Michaeli,et al.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Parfitt Osteonal and hemi‐osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone , 1994, Journal of cellular biochemistry.

[42]  G. Roodman,et al.  ADAM8: A Novel Osteoclast Stimulating Factor , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  J. Penninger,et al.  Role of RANKL and RANK in bone loss and arthritis , 2002, Annals of the rheumatic diseases.

[44]  S. Tuck,et al.  The cell biology of bone metabolism , 2008, Journal of Clinical Pathology.

[45]  M. Padrines,et al.  RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.

[46]  Ruili Li,et al.  Interleukin‐11 Receptor Signaling Is Required for Normal Bone Remodeling , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[47]  Kozo Nakamura,et al.  Connection Between B Lymphocyte and Osteoclast Differentiation Pathways1 , 2001, The Journal of Immunology.

[48]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[49]  L. Lanyon,et al.  Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. , 2003, American journal of physiology. Cell physiology.

[50]  K. Pienta,et al.  The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites , 2008, Leukemia.

[51]  L. Bonewald,et al.  MLO‐Y4 Osteocyte‐Like Cells Support Osteoclast Formation and Activation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[52]  P. Nijweide,et al.  Time-lapse microcinematography of osteocytes. , 1995, Mineral and electrolyte metabolism.

[53]  M H Kroll,et al.  Parathyroid hormone temporal effects on bone formation and resorption , 2000, Bulletin of mathematical biology.

[54]  W. Van Hul,et al.  Wnt signaling: a win for bone. , 2008, Archives of biochemistry and biophysics.

[55]  F. Minuto,et al.  The IGF system and bone. , 2005, Journal of endocrinological investigation.

[56]  Gethin P Thomas,et al.  Vitamin D Action and Regulation of Bone Remodeling: Suppression of Osteoclastogenesis by the Mature Osteoblast , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  Claus Christiansen,et al.  Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity? , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[58]  T. Martin,et al.  Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.

[59]  B. Riggs,et al.  The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated* *This work was supported by Grant AG-04875 from the National Institute on Aging. , 2000, Endocrinology.

[60]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[61]  J. Penninger,et al.  Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. , 2000, The Journal of clinical investigation.